Skip to main content

a16z Capital Management, L.L.C.

13F filer · CIK 0001540358
Reported Aug 14, 2026
Net buyer this quarter
13F portfolio value$14.2BU.S. long equity reported on 13F
Positions193 new · 0 closed
Net flow last quarter+$12.6BBuys minus sells
Top 10 positions weight99.4%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 202619 positions
SPCXSpace Exploration Technologies Corp$12.8B89.97%Not reportedNewQ2 2026
NAVNNavan, Inc.$645M4.54%61.64%Not reportedQ4 2025
RVMDRevolution Medicines, Inc.$173M1.21%0.43%Not reportedQ4 2023
METAMeta Platforms, Inc.$120M0.84%Not reportedNot reportedQ3 2025
FIGFigma, Inc.$108M0.76%Not reported-62.6%Q3 2025
BIOABioAge Labs, Inc.$79.2M0.56%7.06%Not reportedQ3 2024
XYZBlock, Inc.$77.3M0.54%Not reportedNot reportedQ4 2023
ERASErasca, Inc.$52.4M0.37%0.92%Not reportedQ4 2023
MAZEMaze Therapeutics, Inc.$50.8M0.36%3.07%Not reportedQ1 2025
DMRADamora Therapeutics, Inc.$32.2M0.23%2.00%Not reportedQ1 2026
OMDAOmada Health, Inc.$25.3M0.18%1.90%-50.0%Q2 2025
NAUTNautilus Biotechnology, Inc.$16.9M0.12%7.12%-48.7%Q4 2023
RBLXRoblox Corp$14.9M0.11%0.04%NewQ2 2026
AKTSAktis Oncology, Inc.$13.4M0.09%0.78%Not reportedQ1 2026
CAMPCamp4 Therapeutics Corp$9.29M0.07%4.09%Not reportedQ4 2024
BTGOBitgo Holdings, Inc.$3.45M0.02%Not reportedNot reportedQ1 2026
KLRAKailera Therapeutics, Inc.$3.08M0.02%0.11%NewQ2 2026
DNAGinkgo Bioworks Holdings, Inc.$1.08M0.01%0.17%Not reportedQ1 2024
IPSTIp Strategy Holdings, Inc.$9.72K0.00%0.60%Not reportedQ1 2026
Q1 2026Reported May 15, 202616 positions
NAVNNavan, Inc.$374M28.95%61.64%+3.8%Q4 2025
FIGFigma, Inc.$338M26.23%Not reported-1.4%Q3 2025
METAMeta Platforms, Inc.$122M9.42%Not reportedNot reportedQ3 2025
RVMDRevolution Medicines, Inc.$89.6M6.94%0.46%Not reportedQ4 2023
NAUTNautilus Biotechnology, Inc.$68.5M5.31%13.89%Not reportedQ4 2023
XYZBlock, Inc.$61.2M4.74%Not reportedNot reportedQ4 2023
BIOABioAge Labs, Inc.$56.5M4.38%7.28%Not reportedQ3 2024
MAZEMaze Therapeutics, Inc.$50.8M3.94%3.42%Not reportedQ1 2025
ERASErasca, Inc.$46.3M3.59%0.92%Not reportedQ4 2023
DMRADamora Therapeutics, Inc.$32M2.48%2.05%NewQ1 2026
OMDAOmada Health, Inc.$29M2.25%3.89%-33.3%Q2 2025
CAMPCamp4 Therapeutics Corp$9.37M0.73%4.09%Not reportedQ4 2024
AKTSAktis Oncology, Inc.$7.42M0.58%0.78%NewQ1 2026
BTGOBitgo Holdings, Inc.$5.48M0.42%Not reportedNewQ1 2026
DNAGinkgo Bioworks Holdings, Inc.$666K0.05%0.18%Not reportedQ1 2024
IPSTIp Strategy Holdings, Inc.$21.8K0.00%16.09%NewQ1 2026
Q4 2025Reported Feb 17, 202613 positions
FIGFigma, Inc.$607M38.43%Not reportedNot reportedQ3 2025
NAVNNavan, Inc.$464M29.40%59.40%NewQ4 2025
METAMeta Platforms, Inc.$140M8.88%Not reportedNot reportedQ3 2025
RVMDRevolution Medicines, Inc.$73.4M4.64%0.47%-66.5%Q4 2023
MAZEMaze Therapeutics, Inc.$70.5M4.46%3.45%Not reportedQ1 2025
XYZBlock, Inc.$66.2M4.19%Not reportedNot reportedQ4 2023
OMDAOmada Health, Inc.$54.6M3.46%5.92%-25.0%Q2 2025
BIOABioAge Labs, Inc.$44.1M2.79%8.65%Not reportedQ3 2024
NAUTNautilus Biotechnology, Inc.$34.4M2.18%13.96%Not reportedQ4 2023
CAMPCamp4 Therapeutics Corp$13M0.82%4.09%Not reportedQ4 2024
ERASErasca, Inc.$10.6M0.67%1.01%Not reportedQ4 2023
DNAGinkgo Bioworks Holdings, Inc.$902K0.06%0.19%Not reportedQ1 2024
HTBKHeritage Commerce Corp$129K0.01%0.13%NewQ4 2025
Q3 2025Reported Nov 14, 202511 positions
FIGFigma, Inc.$843M60.41%Not reportedNewQ3 2025
METAMeta Platforms, Inc.$156M11.19%Not reportedNewQ3 2025
RVMDRevolution Medicines, Inc.$128M9.20%1.45%Not reportedQ4 2023
OMDAOmada Health, Inc.$102M7.31%7.97%Not reportedQ2 2025
XYZBlock, Inc.$73.5M5.27%Not reportedNot reportedQ4 2023
MAZEMaze Therapeutics, Inc.$44.1M3.16%3.54%Not reportedQ1 2025
BIOABioAge Labs, Inc.$19M1.36%9.02%Not reportedQ3 2024
NAUTNautilus Biotechnology, Inc.$14.9M1.07%13.98%Not reportedQ4 2023
CAMPCamp4 Therapeutics Corp$6.38M0.46%4.53%Not reportedQ4 2024
ERASErasca, Inc.$6.24M0.45%1.01%Not reportedQ4 2023
DNAGinkgo Bioworks Holdings, Inc.$1.58M0.11%0.19%Not reportedQ1 2024
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.